Topic Menu
► Topic MenuTopic Editors

Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors
Topic Information
Dear Colleagues,
We are delighted to announce the initiation of a Topic, "Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors", dedicated to exploring the dynamic intersection of synthetic organic chemistry and biology, with profound implications for diverse medical applications.
Within this specialized topic, our focus is on the synthesis and biological assessment of novel small molecules designed to inhibit multiple enzymes concurrently. Multi-target enzyme inhibitors offer a comprehensive treatment approach by simultaneously targeting multiple disease-related pathways, enhancing therapeutic efficacy. Their ability to mitigate drug resistance, improve selectivity, and potentially provide synergistic effects makes them promising candidates for treating complex diseases. Additionally, the versatility of these inhibitors allows for a more personalized treatment strategy, addressing the multifactorial origins of various medical conditions.
The synthesis process involves optimizing for favorable pharmacokinetic properties and target specificity, leading to a varied library of compounds. The potential applications of the target inhibitors extend into critical areas of medical research, including neurological disorders, the antimicrobial field, antidiabetic therapies, and so on.
We also welcome investigations into novel synthetic methodologies, recognizing their importance in developing innovative strategies to access multi-target inhibitors. Contributions in the form of reviews and original research papers are encouraged for publication. We invite your participation in creating a comprehensive collection of articles, promoting a deeper understanding of the synthesis and evaluation of small molecules with multi-target enzyme-inhibitory properties and the development of novel synthetic routes.
We eagerly anticipate and welcome your valuable contributions to advancing the discourse surrounding this exciting and rapidly evolving field.
Dr. Davide Moi
Prof. Dr. Daniele Passarella
Dr. Andrea Citarella
Topic Editors
Keywords
- organic synthesis
- medicinal chemistry
- enzyme inhibitors
- synthetic methodologies
- bioactive compounds
- drug design
- molecular modelling
- drug discovery
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC | |
---|---|---|---|---|---|---|
![]()
BioChem
|
- | - | 2021 | 21.7 Days | CHF 1000 | Submit |
![]()
Biomolecules
|
4.8 | 9.4 | 2011 | 18.4 Days | CHF 2700 | Submit |
![]()
Current Issues in Molecular Biology
|
2.8 | 2.9 | 1999 | 15.8 Days | CHF 2200 | Submit |
![]()
Molecules
|
4.2 | 7.4 | 1996 | 15.1 Days | CHF 2700 | Submit |
![]()
Pharmaceutics
|
4.9 | 7.9 | 2009 | 15.5 Days | CHF 2900 | Submit |
![]()
Scientia Pharmaceutica
|
2.3 | 4.6 | 1930 | 26.1 Days | CHF 1000 | Submit |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.